Inhibition of FGFR1 could induce autophagy in FGFR1‐amplified lung squamous cell carcinoma cells, and simultaneously blockade of both FGFR1 and autophagy could enhance cell death.[25] These findings suggested that autophagy and FGFR1 inhibitor may be promising AZD9291‐sensitizers, and simultaneous inhibition of autophagy and FGFR1 on AZD9291 resistant NSCLC cells could potentially enhance the efficacy of AZD9291 treatment. Here, FGFR1 is linked to non-small cell lung carcinoma.